Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B

The number of new cases of emerging fungal infections has increased considerably in recent years, mainly due to the large number of immunocompromised individuals. The objective of this study was to evaluate the susceptibility of emerging fungi to fluconazole, itraconazole and amphotericin B by disk...

Descripción completa

Detalles Bibliográficos
Autores principales: Fay, Vanessa da Silva, Rodrigues, Diana Mara Garcia, Gonçalves, Stela Maris Bottin, Gregianini, Tatiana Schaffer, Bonamigo, Renan Rangel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2018
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001099/
https://www.ncbi.nlm.nih.gov/pubmed/29924220
http://dx.doi.org/10.1590/abd1806-4841.20187364
Descripción
Sumario:The number of new cases of emerging fungal infections has increased considerably in recent years, mainly due to the large number of immunocompromised individuals. The objective of this study was to evaluate the susceptibility of emerging fungi to fluconazole, itraconazole and amphotericin B by disk diffusion method. In 2015, 82 emerging fungi were evaluated in IPB-LACEN/RS and 13 (15.8%) were resistant: 10/52 were from superficial mycoses and 3/30 from systemic mycoses. The data from the study point to the need for permanent vigilance regarding the careful evaluation in the prescription and clinical and laboratory follow-up of patients affected by fungal infections.

Ejemplares similares